Popular Pre-Market Trades in U.S. Stocks

Troops, up 7.25% in pre-market, has no significant news recently. Trading is active, with clear capital flows. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

Top Gainers in Pre-Market U.S. Stocks

Q32 Bio is up 71.63% in pre-market. Based on recent key news:

1. On July 13, Q32 Bio announced that its drug bempikibart showed significant efficacy in treating patients with severe alopecia areata, leading to a rise in stock price. In a 36-week treatment, patients experienced an average hair regrowth improvement of 35.3%, with about 40% of patients achieving significant scalp coverage.

2. On July 13, the company plans to conduct larger-scale registration studies in 2027 and will announce more results at future medical conferences, further boosting market confidence.

3. On July 13, bempikibart demonstrated strong clinical activity and good safety, supporting the advancement of registration studies and highlighting its potential to meet significant unmet needs in the U.S. market. The biotechnology sector has performed strongly recently, with noticeable capital inflows.

LogProstyle is up 63.52% in pre-market. Based on recent news,

1. On July 13, LogProstyle announced a cash dividend of $0.046 per share, totaling $1.09 million, to be paid quarterly over the next 12 months. This news boosted investor confidence, driving the stock price significantly higher.

2. On July 13, LogProstyle is expected to announce its earnings report for the fiscal year 2026, and the market is full of expectations for its performance, further driving the stock price up.

3. On July 13, LogProstyle released detailed information about the aforementioned dividend and earnings report expectations through the EDGAR system, increasing information transparency and further enhancing market confidence. The market reacted positively to LogProstyle's dividend and earnings report expectations.

Antigenis is up 60.24% in pre-market. Based on recent news,

1. On July 13, Antigenis announced it secured up to $340 million in private financing, led by Commodore Capital, with participation from RA Capital Management and others. This financing will support its experimental cancer drug combination botensilimab and balstilimab in late-stage trials for high-risk colorectal cancer patients. The financing includes an $85 million upfront payment and up to $255 million in warrant exercise funds, expected to support the company's operations until 2031. This news drove the stock price up by 22.4%.

2. On July 13, Antigenis announced it would cease funding for another study on late-stage colorectal cancer to concentrate resources on the new trial. This move indicates a strategic adjustment by the company, focusing on more promising projects, further boosting market confidence On July 13, Antengene announced its plan to start recruiting patients in early 2027 and report preliminary results later that year. This news boosted investor confidence in the company's future development, driving up the stock price. The biotechnology industry has performed strongly recently, with frequent financing activities